Fmr LLC Has $301.85 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

FMR LLC boosted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 2.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,367,979 shares of the company's stock after acquiring an additional 357,470 shares during the quarter. FMR LLC owned 11.04% of 10x Genomics worth $301,849,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock valued at $35,000 after acquiring an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics in the third quarter valued at about $35,000. Allspring Global Investments Holdings LLC raised its position in shares of 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock valued at $32,000 after purchasing an additional 939 shares during the period. Blue Trust Inc. lifted its stake in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after buying an additional 1,025 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock worth $37,000 after buying an additional 808 shares during the period. 84.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

TXG has been the subject of several research reports. Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, October 30th. Citigroup lowered their price objective on 10x Genomics from $35.00 to $23.00 and set a "buy" rating on the stock in a research report on Wednesday, October 30th. Leerink Partners began coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They issued an "outperform" rating and a $35.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of 10x Genomics to a "strong-buy" rating in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.19.

10x Genomics Trading Up 2.7 %

NASDAQ TXG traded up $0.42 on Friday, hitting $15.90. 960,890 shares of the company's stock were exchanged, compared to its average volume of 2,172,935. The stock has a 50-day moving average of $16.89 and a 200-day moving average of $19.50. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -10.39 and a beta of 1.87. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $57.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The business had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. During the same period in the prior year, the company earned ($0.51) EPS. 10x Genomics's revenue for the quarter was down 1.3% on a year-over-year basis. As a group, analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.